厄贝沙坦联合胺碘酮治疗充血性心力衰竭合并室性心律失常的临床观察

目的探讨厄贝沙坦联合胺碘酮治疗充血性心力衰竭合并室性心律失常的临床疗效。方法选取2011年1月—2012年1月来该院就诊的充血性心力衰竭合并室性心律失常患者40例作为研究对象,40例患者分为观察组和对照组各20例,两组患者均予强心剂、利尿剂、β受体阻滞剂及扩血管药物,同时予胺碘酮200mg,口服3次/d,1周后改为2次/d,2周后改为1次/d,逐渐减小到维持量。观察组在此基础上加用厄贝沙坦80mg/d口服,如无不适,改为160mg/d。结果观察组患者心功能治疗后较对照组的疗效明显提高,组间比较差异有统计学意义（P〈0.05）。观察组的室性心律失常患者治疗后较对照组的疗效显著提高,组间比较差异有统计学意义（P〈0.05）。结论厄贝沙坦联合胺碘酮治疗充血性心力衰竭合并室性心律失常可以提高临床疗效,且安全性好,值得推广和应用。

The Clinical Observation of Irbesartan and Amiodarone in the Treatment of Patients with Congestive Heart Failure Accompanied with Ventricular Arrhythmia

Objective To observe the efficacy of Irbesartan and amiodarone in the treatment of patients with congestive heart failure and ventricular arrhythmia. Methods 40 patients with congestive heart failure and ventricular arrhythmia admitted in our hospital from January, 2011 to January, 2012 were divided into observation group and control group with 20 patients in each group. The two groups of patients were given cardiac stimulants, diuretics, β-blockers and vasodilators. At the same time, amiodarone was given to them, 200 mg, 3 times a day orally, 1 week later changed to 2 times a day, 2 weeks later to 1 time a day, and gradually reduced to maintenance dose. Based on the above, the observation group was given irbesartan 80 mg/d orally in addition, and added to 160 mg/d if the patients had no discomfort. Results After treatment, the efficacy of the cardiac function of the observation group and the efficacy of patients with ventricular arrhythmias in the observation group were significantly better than those of the control group, the differences between the two groups were statistically significant （P0.05）. Conclusion Irbesartan combined with amiodarone in treatment of congestive heart failure accompanied with ventricular arrhythmia can improve the clinical efficacy with good safety, which is worthy of promotion and application.